Drug intelligence / Profile preview

REGEND-004

Development stage: Preclinical
Lead developer: Regend Therapeutics
Modality: Cell Therapies

Overview

REGEND-004 is a cell therapy drug candidate developed by Regend Therapeutics. It is currently in preclinical development, with its primary indication being fibrosis. The specific mechanism of action and cellular modality details have not been disclosed publicly as of the latest available update. The therapy falls under the broader category of cell therapies targeting fibrotic diseases[1].

Beyond the preview

Go deeper on REGEND-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGEND-004.

Explore the full profile